MedTrace Logo

NTLA-2002 in Adults With Hereditary Angioedema (HAE)

NCT05120830 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2026-03-24

No results posted yet for this study

Summary

This study will be conducted to evaluate the safety, tolerability, activity, pharmacokinetics, and pharmacodynamics of NTLA-2002 in adults with Hereditary Angioedema (HAE).

Conditions

Interventions

BIOLOGICAL

Biological NTLA-2002

CRISPR/Cas9 gene editing system delivered by LNP for IV administration

OTHER

Normal Saline IV Administration

The administration of IV normal saline

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-10
Primary Completion
2024-04-04
Completion
2026-07-31

Countries

  • Australia
  • France
  • Germany
  • Netherlands
  • New Zealand
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05120830 on ClinicalTrials.gov